Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

NCT02274740 · Terminated

Last updated 2026-05-28

This clinical trial tested the effect of the medication lixisenatide on blood fat levels after meals in adults with type 2 diabetes and obesity over a 10-week period.

Status Terminated Stopped early and will not restart.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 2 people

Who can join Ages 18–70 · all sexes

Timeline Started 2015-04 · est. completion 2015-08

What this study is testing ClinicalTrials.gov NCT02274740 ↗

Description as written by the study sponsor.

Primary Objective: To evaluate the ability of lixisenatide to modulate postprandial hyperlipidemia in particular, the effects on plasma changes in triglycerides. Secondary Objectives: The effect of lixisenatide on the following postprandial lipids: apolipoprotein (APO) B48; free fatty acid, lipoprotein distribution, cholesterol, and low-density lipoprotein (LDL) oxidation. The effect of lixisenatide on chronic low-grade inflammation present in non-insulin dependent diabetes mellitus (NIDDM) and obesity. The effect of lixisenatide on microvascular dysfunction. To evaluate the effect of lixisenatide on postprandial plasma glucose, insulin and C-peptide and glucagon.

Treatments tested

LIXISENATIDE AVE0010 Drug

Pharmaceutical form:solution Route of administration: subcutaneous
metformin Drug

Pharmaceutical form:tablet Route of administration: oral

Main thing measured	Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min)
Sponsor	Sanofi
Conditions studied	Type II Diabetes Mellitus
GLP-1 drugs	lixisenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02274740 ↗